What did @emmy.b.glp1 actually say?
This video is straightforward: a first-time Wegovy user documenting her week-one injection at the starting dose of 0.25 mg. She walks through hand-washing, alcohol swabbing, letting the site dry, checking for liquid in the pen, and counting to ten after pressing the plunger. She ends by confirming she sees the yellow indicator bar. No dramatic claims, no supplement stacks, no miracle promises. Just a woman showing what the first shot looks like.
The hashtag context matters here. She tags perimenopause alongside semaglutide, which is increasingly relevant given that hormonal shifts during perimenopause are associated with fat redistribution and metabolic changes that can make weight management harder. She doesn't explicitly claim Wegovy treats perimenopause symptoms, though the pairing clearly implies a connection in her personal journey.
Does the science back this up?
Her injection technique is largely consistent with what the clinical literature and manufacturer guidance support. The upper thigh is one of three approved injection sites for Wegovy, alongside the abdomen and upper arm. Her step-by-step approach matches the core safety steps: clean hands, alcohol prep, air-dry before injecting, confirm dose completion via the indicator window.
The ten-second hold she counts out matters more than most people realize. Novo Nordisk's prescribing information specifies holding the pen in place until the yellow bar appears and stops moving, which typically requires several seconds to ensure full dose delivery. Research on auto-injector pens broadly shows that premature removal is one of the more common patient errors. A 2021 review by Berard et al. in the journal Expert Opinion on Drug Delivery found that patient training on auto-injector technique significantly reduces delivery failures. She didn't rush it. That's worth noting.
On the perimenopause angle, a 2023 study by Erin Kershaw's group published in Menopause found GLP-1 receptor agonists showed meaningful weight loss results in perimenopausal and postmenopausal women, though the mechanisms interact with estrogen decline in ways that aren't fully mapped yet.
What did they get wrong (or right)?
Honestly, she got most of it right. The technique she demonstrates aligns with standard guidance. Hand washing before injection is a basic but frequently skipped step that matters for sterility. Checking that the pen contains liquid before injecting is smart, and something first-timers often forget. The alcohol swab followed by waiting for the site to dry is correct because injecting through wet alcohol can cause brief stinging and potentially affect skin integrity over repeated use.
One minor gap: she rolls up her pant leg to inject into the upper thigh, which is fine, but she doesn't visibly pinch the skin. For someone at 160 pounds on a thigh injection, this likely isn't a problem since there's adequate subcutaneous tissue. However, for leaner individuals, skipping the skin pinch can increase the risk of intramuscular injection, which isn't dangerous but can increase soreness and may alter absorption timing. She should have mentioned this for the 351,000 people watching.
She also doesn't mention rotating injection sites, which the prescribing information recommends to avoid lipohypertrophy, the lumpy fatty tissue buildup that develops from repeated injections at the same spot. That's a genuine omission for a video this widely viewed.
What should you actually know?
If you're starting Wegovy, her video is a decent rough guide, but not a substitute for reading the Instructions for Use that comes with your pen or talking to your prescriber. The yellow indicator bar she references is a real and important feature. The ten-second count is real. The alcohol dry-time step is real. These aren't just theater.
A few things her video doesn't cover that matter: injection site rotation across sessions, what to do if the yellow bar doesn't fully appear, proper pen storage between uses (refrigerated until first use, then room temperature for up to 28 days), and what to expect in the first week in terms of side effects. Nausea affects roughly 44 percent of Wegovy users in clinical trials, peaking in weeks two through four according to the STEP 1 trial published by Wilding et al. in the New England Journal of Medicine in 2021.
The perimenopause framing she uses is worth watching in the research space. Emerging data suggest GLP-1 agonists may have particular utility for women in this hormonal transition, but no regulatory agency has approved semaglutide specifically for perimenopausal weight management. Anyone pursuing this combination should be working with a clinician who understands both endocrinology and metabolic medicine.